Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

Table 3 Predictors of the number of serotypes (0–12) with positive antibody response, i.e., ≥ 2-fold increase from prevaccination serotype-specific [IgG], after prime-boost vaccination

	Stepwise selection of exposure variables, p of likelihood ratio test				Multivariate linear regression model
Predictors:	1	2	3	4	Coefficient estimate	95% CI	p
Intercept (control)					11.2	10.3, 12.1	< 0.001
Rituximab (yes/no)	< 0.001	< 0.001	< 0.001	< 0.001	− 8.6	− 9.8, − 7.4	< 0.001
Abatacept (yes/no)	0.008	0.009	0.009	0.007	− 1.9	− 3.2, − 0.6	0.005
cDMARD (yes/no)	< 0.001	< 0.001	< 0.001	< 0.001	− 1.8	− 2.8, − 0.8	< 0.001
Gender	0.11	0.13	0.13	0.10	Goodness of fit: multiple R² = 0.69
Age (years)	0.59	–	–	–
CRP (mg/L)	0.38	0.39	0.36	–
Prednisolone dose (mg/day)	0.56	0.63	–	–

ISSN: 1478-6362